These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 28551545)
21. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Hirose Y; Berger MS; Pieper RO Cancer Res; 2001 Mar; 61(5):1957-63. PubMed ID: 11280752 [TBL] [Abstract][Full Text] [Related]
22. Sulfasalazine intensifies temozolomide cytotoxicity in human glioblastoma cells. Ignarro RS; Facchini G; Vieira AS; De Melo DR; Lopes-Cendes I; Castilho RF; Rogerio F Mol Cell Biochem; 2016 Jul; 418(1-2):167-78. PubMed ID: 27334753 [TBL] [Abstract][Full Text] [Related]
23. Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells. Paul-Samojedny M; Pudełko A; Kowalczyk M; Fila-Daniłow A; Suchanek-Raif R; Borkowska P; Kowalski J BioDrugs; 2016 Apr; 30(2):129-44. PubMed ID: 26902608 [TBL] [Abstract][Full Text] [Related]
24. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma. Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605 [TBL] [Abstract][Full Text] [Related]
25. Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy. Golden EB; Cho HY; Jahanian A; Hofman FM; Louie SG; Schönthal AH; Chen TC Neurosurg Focus; 2014 Dec; 37(6):E12. PubMed ID: 25434381 [TBL] [Abstract][Full Text] [Related]
26. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279 [TBL] [Abstract][Full Text] [Related]
27. Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Hirose Y; Berger MS; Pieper RO Cancer Res; 2001 Aug; 61(15):5843-9. PubMed ID: 11479224 [TBL] [Abstract][Full Text] [Related]
28. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma. Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370 [TBL] [Abstract][Full Text] [Related]
29. Intracellular cholesterol level regulates sensitivity of glioblastoma cells against temozolomide-induced cell death by modulation of caspase-8 activation via death receptor 5-accumulation and activation in the plasma membrane lipid raft. Yamamoto Y; Tomiyama A; Sasaki N; Yamaguchi H; Shirakihara T; Nakashima K; Kumagai K; Takeuchi S; Toyooka T; Otani N; Wada K; Narita Y; Ichimura K; Sakai R; Namba H; Mori K Biochem Biophys Res Commun; 2018 Jan; 495(1):1292-1299. PubMed ID: 29162448 [TBL] [Abstract][Full Text] [Related]
30. Combination therapy with micellarized cyclopamine and temozolomide attenuate glioblastoma growth through Gli1 down-regulation. Liu YJ; Ma YC; Zhang WJ; Yang ZZ; Liang DS; Wu ZF; Qi XR Oncotarget; 2017 Jun; 8(26):42495-42509. PubMed ID: 28477008 [TBL] [Abstract][Full Text] [Related]
31. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000 [TBL] [Abstract][Full Text] [Related]
32. The synergistic effect of combination temozolomide and chloroquine treatment is dependent on autophagy formation and p53 status in glioma cells. Lee SW; Kim HK; Lee NH; Yi HY; Kim HS; Hong SH; Hong YK; Joe YA Cancer Lett; 2015 May; 360(2):195-204. PubMed ID: 25681668 [TBL] [Abstract][Full Text] [Related]
33. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma. Tian T; Mingyi M; Qiu X; Qiu Y Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996 [TBL] [Abstract][Full Text] [Related]
34. MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells. Wong ST; Zhang XQ; Zhuang JT; Chan HL; Li CH; Leung GK Anticancer Res; 2012 Jul; 32(7):2835-41. PubMed ID: 22753745 [TBL] [Abstract][Full Text] [Related]
35. Inhibition of JNK potentiates temozolomide-induced cytotoxicity in U87MG glioblastoma cells via suppression of Akt phosphorylation. Vo VA; Lee JW; Lee HJ; Chun W; Lim SY; Kim SS Anticancer Res; 2014 Oct; 34(10):5509-15. PubMed ID: 25275048 [TBL] [Abstract][Full Text] [Related]
36. Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors. Wang Z; Yang J; Xu G; Wang W; Liu C; Yang H; Yu Z; Lei Q; Xiao L; Xiong J; Zeng L; Xiang J; Ma J; Li G; Wu M Oncotarget; 2015 Feb; 6(5):3147-64. PubMed ID: 25605243 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. Kanzawa T; Bedwell J; Kondo Y; Kondo S; Germano IM J Neurosurg; 2003 Dec; 99(6):1047-52. PubMed ID: 14705733 [TBL] [Abstract][Full Text] [Related]